Innohep

tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injectable solution for subcutaneous use. It is employed to prevent and treat deep vein thrombosis, pulmonary embolism, and other thromboembolic conditions in surgical and medical patients. It is marketed in the European Union and is available by prescription for use under medical supervision.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance, and reliable cold‑chain logistics for injectable products.

Innohep, a low molecular weight heparin, is used in several thromboembolic conditions.

- Deep vein thrombosis (DVT) prophylaxis: prevents clot formation in surgical patients at risk of DVT. - Acute deep vein thrombosis treatment: facilitates clot resolution and reduces propagation in patients with confirmed DVT. - Pulmonary embolism prevention and treatment: lowers the risk of embolic events in patients with or after a pulmonary embolism. - Thromboembolic event prophylaxis: reduces clot risk in medically ill patients prone to venous thromboembolism.

Innohep may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain or erythema - Bruising at the injection site - Mild bleeding (e.g., nosebleeds, gum bleeding) - Nausea

Serious or Rare Side Effects: - Severe or uncontrolled bleeding - Heparin‑induced thrombocytopenia - Allergic reactions including anaphylaxis - Skin necrosis at the injection site

When using Innohep, several precautions should be observed to minimize risk.

- Renal impairment: assess renal function and adjust dose or monitor closely. - History of heparin‑induced thrombocytopenia: avoid use due to risk of recurrence. - Concurrent anticoagulants or antiplatelet therapy: increased bleeding risk, consider temporary discontinuation. - Surgery or invasive procedures: discontinue Innohep prior to the procedure as advised by the clinician. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Innohep can interact with other medicines, affecting its anticoagulant effect.

Major Interactions (Avoid): - Other parenteral anticoagulants (e.g., unfractionated heparin, direct thrombin inhibitors): additive anticoagulation may cause severe bleeding. - Thrombolytic agents (e.g., alteplase, streptokinase): combined use markedly increases hemorrhagic risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin: may enhance bleeding tendency. - Antiplatelet agents (e.g., clopidogrel, ticagrelor): additive effect on platelet inhibition. - Certain antibiotics (e.g., quinolones) that may affect platelet function: monitor for bleeding signs.